Oncology Medications

LUMAKRAS™
(sotorasib)

LUMAKRAS now available from Onco360!

 LUMAKRAS(sotorasib) is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

 Dosage and Administration 1

The recommended dose for LUMAKRAS is 960 mg (eight 120 mg tablets) orally once daily. 

Dosage Forms and Strengths 

LUMAKRAS is available in 120 mg tablets. 

  • Carton containing two bottles of 120 tablets (NDC 55513-488-02)
  • Carton containing one bottle of 240 tablets (NDC 55513-488-24) 

 

For more information, visit LUMAKRAS.com 

How to Order

Call

Call 877-662-6633.

Fax

Download the Oral Rx
Oncology Order Form and
fax it to 877-662-6355.
Oral Order Form

e-Prescribe

e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.

 1LUMAKRAS™ Prescribing Information: Amgen, Inc. accessed 6/2021. LUMAKRAS™ trademark is owned or licensed by Amgen, Inc.